Alkermes plc - Ordinary Shares (NQ:ALKS)

46.83 -0.58 (-1.22%)

Streaming Delayed Price Updated: 3:44 PM EDT, Aug 31, 2026 Add to My Watchlist

Price and Volume

Volume	735,711
Open	47.25
Bid (Size)	46.81 (100)
Ask (Size)	46.86 (200)
Prev. Close	47.41
Today's Range	46.46 - 47.56
52wk Range	25.16 - 55.67
Shares Outstanding	166,121,384
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 ↗

August 29, 2026

The insider still has significant holdings in the company, signaling confidence.

Via The Motley Fool

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

August 24, 2026

From Alkermes plc

Via Business Wire

Performance

YTD	+65.7%	+65.7%
1 Month	-4.4%	-4.4%
3 Month	+10.8%	+10.8%
6 Month	+54.8%	+54.8%
1 Year	+59.3%	+59.3%

More News

Alkermes Q2 Earnings Call Highlights ↗

July 28, 2026

Via MarketBeat

Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance ↗

July 28, 2026

Via Chartmill

Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗

May 05, 2026

Via Chartmill

Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗

April 29, 2026

Via Chartmill

Alkermes plc Reports Second Quarter 2026 Financial Results

July 28, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Second Quarter Financial Results on July 28, 2026

July 14, 2026

From Alkermes plc

Via Business Wire

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

July 13, 2026

From Alkermes plc

Via Business Wire

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

June 17, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

June 15, 2026

From Alkermes plc

Via Business Wire

Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗

June 10, 2026

Via MarketBeat

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

June 04, 2026

From Alkermes plc

Via Business Wire

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 03, 2026

From Alkermes plc

Via Business Wire

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

May 26, 2026

From Alkermes plc

Via Business Wire

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

May 21, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

May 12, 2026

From Alkermes plc

Via Business Wire

Alkermes (ALKS) Q1 2026 Earnings Transcript ↗

May 05, 2026

Via The Motley Fool

Alkermes plc Reports First Quarter 2026 Financial Results

May 05, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report First Quarter Financial Results on May 5, 2026

April 21, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

April 16, 2026

From Alkermes plc

Via Business Wire

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

April 14, 2026

From Alkermes plc

Via Business Wire

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

Via MarketMinute

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

April 01, 2026

From Alkermes plc

Via Business Wire

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Via Finterra

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?

Yes, Alkermes plc - Ordinary Shares is publicly traded.

What exchange does Alkermes plc - Ordinary Shares trade on?

Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alkermes plc - Ordinary Shares?

The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market

What is the current price of Alkermes plc - Ordinary Shares?

The current price of Alkermes plc - Ordinary Shares is 46.83

When was Alkermes plc - Ordinary Shares last traded?

The last trade of Alkermes plc - Ordinary Shares was at 08/31/26 03:44 PM ET

What is the market capitalization of Alkermes plc - Ordinary Shares?

The market capitalization of Alkermes plc - Ordinary Shares is 7.78B

How many shares of Alkermes plc - Ordinary Shares are outstanding?

Alkermes plc - Ordinary Shares has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.